Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DOT1L | Q8TEK3 | 6/20 | 0.68 |
| ▸ | AHCY | P23526 | 2/20 | 0.55 |
| ▸ | PRKACA | P17612 | 2/20 | 0.54 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.53 |
| ▸ | NNMT | P40261 | 1/20 | 0.53 |
| ▸ | WDR5 | P61964 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | RBBP5 | Q15291 | 1/20 | 0.51 |
| ▸ | DPY30 | Q9C005 | 1/20 | 0.51 |
| ▸ | ASH2L | Q9UBL3 | 1/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16574770 | 0.86 | DOT1L (0.60) | DOT1LAHCYPRKACA | |
| SCHEMBL29540124 | 0.82 | DOT1L (0.61) | DOT1LAHCYPRKACACARM1NNMT | |
| SCHEMBL23056492 | 0.82 | DOT1L (0.51) | DOT1LPRKACACARM1ADORA1 | |
| SCHEMBL16287415 | 0.81 | DOT1L (0.50) | DOT1L | |
| SCHEMBL16287441 | 0.81 | DOT1L (0.50) | DOT1L | |
| SCHEMBL16287434 | 0.81 | DOT1L (0.50) | DOT1L | |
| SCHEMBL16287421 | 0.81 | DOT1L (0.50) | DOT1L | |
| SCHEMBL16578333 | 0.81 | DOT1L (0.50) | DOT1L | |
| SCHEMBL16287429 | 0.81 | DOT1L (0.50) | DOT1L | |
| SCHEMBL23056483 | 0.80 | DOT1L (0.51) | DOT1LPRKACAADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150080549-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080549-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | DOT1L 4554/4885AHCY 3672/4885PRKACA 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.